$Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial$

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Most patients with advanced-stage indolent non-Hodgkin lymphoma have multiple relapses. We assessed axicabtagene ciloleucel autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory indolent non-Hodgkin lymphoma. ZUMA-5 is a single-arm, multicentre, phase 2 trial...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2022-01, Vol.23 (1), p.91-103
Hauptverfasser:	Jacobson, Caron A, Chavez, Julio C, Sehgal, Alison R, William, Basem M, Munoz, Javier, Salles, Gilles, Munshi, Pashna N, Casulo, Carla, Maloney, David G, de Vos, Sven, Reshef, Ran, Leslie, Lori A, Yakoub-Agha, Ibrahim, Oluwole, Olalekan O, Fung, Henry Chi Hang, Rosenblatt, Joseph, Rossi, John M, Goyal, Lovely, Plaks, Vicki, Yang, Yin, Vezan, Remus, Avanzi, Mauro P, Neelapu, Sattva S
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Aged Antigens Biological Products - adverse effects Biological Products - therapeutic use CD19 antigen CD20 antigen Cell therapy Chemotherapy Chimeric antigen receptors Clinical trials Cyclophosphamide Cytokines Female Fludarabine Humans Immunotherapy, Adoptive Laboratories Leukapheresis Life Sciences Lymphocytes T Lymphoma Lymphoma, Non-Hodgkin - drug therapy Male Manufacturing Middle Aged Monoclonal antibodies Non-Hodgkin's lymphoma Patients Recurrence Response rates
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!